Cybernet Data Systems Inc.

Cybernet Data Systems Inc.

ImmunoGen Announces FDA Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer

ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has accepted and filed the Biologics License Application (BLA) for mirvetuximab soravtansine monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer

Cybernet Data Systems Inc.

Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA(R) (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer

Seagen Inc. announced positive topline results from the pivotal phase 2 MOUNTAINEER clinical trial investigating TUKYSA(R) (tucatinib) in combination with trastuzumab in patients with previously treated HER2-positive metastatic colorectal cancer. The combination of tucatinib and trastuzumab showed a 38.1% confirmed objective response rate (cORR) with a median duration